To address the upcoming patent expiration challenge for its cancer drug Keytruda, Merck & Co. has announced a spin-off and restructuring of its pharmaceutical business unit.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
"Big Short" Burry increases short positions on Nasdaq 100 and semiconductors, says Nvidia (NVDA.US) influence may enter a "new paradigm"
"The Big Short" Michael Burry has increased his bearish bets on the Nasdaq 100 Index and semiconductor stocks.
Duan Yongping: Currently will not sell Nvidia, and in the future Jensen Huang may return as a “shadow CEO”
Duan Yongping has made it clear that he will not sell Nvidia and sold a large number of put options on the day the news was released. Nvidia may invite Jensen Huang to serve as an advisor, taking on a “shadow CEO” role to retain his influence, but he would no longer have signing authority. Whether this scenario materializes will likely only become clear after the hearing concludes.
US Research Review - Azenta, Cencora, Stratasys
After Jensen Huang stepped down, Nvidia (NVDA.US) shares plunged; retail investors bought up $111 million within half an hour of the market opening.
Retail investors are still betting on a rebound in NVIDIA (NVDA.US) stock price.
Crypto prices
More
